Cargando…

Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis

The selective T‐cell costimulation modulator abatacept is approved for treatment of adult rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA; 6‐17 years [intravenous] and 2‐17 years [subcutaneous]). An extrapolation approach was taken to determine subcutaneous weight‐tie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandhi, Yash, Passarell, Julie A., Roy, Amit, Murthy, Bindu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Pediatric Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048692/ https://www.ncbi.nlm.nih.gov/pubmed/33284480 http://dx.doi.org/10.1002/jcph.1797

Ejemplares similares

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
por: Brunner, Hermine I., et al.
Publicado: (2020)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Advances in the treatment of polyarticular juvenile idiopathic arthritis
por: Webb, Kate, et al.
Publicado: (2015)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis
por: Li, Xiaohui, et al.
Publicado: (2018)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Brief Report: The Genetic Profile of Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis
por: Hinks, Anne, et al.
Publicado: (2018)

Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches
por: Oberle, Edward J, et al.
Publicado: (2014)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
por: Hara, Ryoki, et al.
Publicado: (2019)

Whole Blood Gene Expression Profiling Predicts Therapeutic Response at Six Months in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Jiang, Kaiyu, et al.
Publicado: (2014)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study
por: Nagy, Arnold, et al.
Publicado: (2020)

Radiological cervical spine involvement in polyarticular idiopathic juvenile arthritis
por: Wipff, J, et al.
Publicado: (2011)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials
por: Mora, Johanna R., et al.
Publicado: (2021)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2021)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis
por: Jones, Nicholas T, et al.
Publicado: (2023)

Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years
por: Lovell, Daniel J., et al.
Publicado: (2015)

Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis
por: Marangoni, Roberta Gonçalves, et al.
Publicado: (2011)

Slow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis
por: Sule, Sangeeta D, et al.
Publicado: (2019)

Study of the shared gene signatures of polyarticular juvenile idiopathic arthritis and autoimmune uveitis
por: Zheng, Jie, et al.
Publicado: (2023)

High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy
por: Mor‐Vaknin, Nirit, et al.
Publicado: (2018)

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
por: Leu, Jocelyn H., et al.
Publicado: (2022)

Isolated Facet Joint Arthritis in Juvenile Idiopathic Arthritis
por: Martone, Giulia, et al.
Publicado: (2021)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

PAIN PERCEPTION AND PAIN COPING MECHANISMS IN CHILDREN AND ADOLESCENTS WITH JUVENILE FIBROMYALGIA AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
por: Fraga, Melissa Mariti, et al.
Publicado: (2018)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2018)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

JAK inhibitors in systemic juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review
por: Chaplin, Hema, et al.
Publicado: (2021)

Childhood-Onset COPA Syndrome Recognized Retrospectively in the Context of Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis
por: Nikolic, Roko P. A., et al.
Publicado: (2023)

PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study
por: Hissink Muller, PC, et al.
Publicado: (2013)

Polyarticular juvenile idiopathic arthritis (pJIA): clinical and serologic predictors of inactive disease (ID)
por: Meiorin, Silvia
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2pri8e8l8mkmqos15hk6cn0qr5